Agenus Inc (AGEN)
10.86
+0.36
(+3.43%)
USD |
NASDAQ |
May 17, 16:00
10.86
0.00 (0.00%)
After-Hours: 20:00
Agenus Accounts Payable (Quarterly): 50.69M for March 31, 2024
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 50.69M |
December 31, 2023 | 61.45M |
September 30, 2023 | 40.87M |
June 30, 2023 | 52.47M |
March 31, 2023 | 46.77M |
December 31, 2022 | 40.94M |
September 30, 2022 | 39.71M |
June 30, 2022 | 41.00M |
March 31, 2022 | 34.54M |
December 31, 2021 | 30.49M |
September 30, 2021 | 25.12M |
June 30, 2021 | 19.16M |
March 31, 2021 | 19.48M |
December 31, 2020 | 17.02M |
September 30, 2020 | 20.54M |
June 30, 2020 | 20.70M |
March 31, 2020 | 14.75M |
December 31, 2019 | 13.56M |
September 30, 2019 | 16.42M |
June 30, 2019 | 19.05M |
March 31, 2019 | 12.73M |
December 31, 2018 | 13.62M |
September 30, 2018 | 11.15M |
June 30, 2018 | 10.23M |
March 31, 2018 | 5.407M |
Date | Value |
---|---|
December 31, 2017 | 8.087M |
September 30, 2017 | 6.720M |
June 30, 2017 | 4.572M |
March 31, 2017 | 4.818M |
December 31, 2016 | 5.428M |
September 30, 2016 | 3.268M |
June 30, 2016 | 5.022M |
March 31, 2016 | 2.513M |
December 31, 2015 | 4.489M |
September 30, 2015 | 3.091M |
June 30, 2015 | 2.662M |
March 31, 2015 | 3.973M |
December 31, 2014 | 1.711M |
September 30, 2014 | 2.259M |
June 30, 2014 | 0.9299M |
March 31, 2014 | 1.681M |
December 31, 2013 | 0.8347M |
September 30, 2013 | 0.3654M |
June 30, 2013 | 0.4218M |
March 31, 2013 | 0.5816M |
December 31, 2012 | 0.6348M |
September 30, 2012 | 0.4678M |
June 30, 2012 | 0.6321M |
March 31, 2012 | 0.3405M |
December 31, 2011 | 0.8079M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
13.56M
Minimum
Dec 2019
61.45M
Maximum
Dec 2023
31.24M
Average
27.80M
Median
Accounts Payable (Quarterly) Benchmarks
Ligand Pharmaceuticals Inc | 1.893M |
Protalix BioTherapeutics Inc | 3.146M |
InfuSystems Holdings Inc | 9.796M |
PAVmed Inc | 1.485M |
Allogene Therapeutics Inc | 5.779M |